190 related articles for article (PubMed ID: 1740047)
1. Dialysis-related amyloidosis and high-flux membranes.
Floege J; Smeby L
Contrib Nephrol; 1992; 96():124-37. PubMed ID: 1740047
[No Abstract] [Full Text] [Related]
2. [Beta 2-microglobulin--its role in renal failure and hemodialysis therapy].
Czyz W; Szepietowski T
Postepy Hig Med Dosw; 1992; 46(2):209-38. PubMed ID: 1470582
[TBL] [Abstract][Full Text] [Related]
3. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
Floege J; Koch KM
Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
[No Abstract] [Full Text] [Related]
4. [Amyloidosis of the dialysis patient].
van Ypersele de Strihou C
Bull Mem Acad R Med Belg; 1988; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
[No Abstract] [Full Text] [Related]
5. [Beta 2-microglobulin and dialysis-related amyloidosis].
Gejyo F
Rinsho Byori; 2001 Mar; 49(3):244-8. PubMed ID: 11307323
[TBL] [Abstract][Full Text] [Related]
6. beta 2-Microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type.
Van Ypersele de Strihou C
Nephrol Dial Transplant; 1996; 11 Suppl 2():147-9. PubMed ID: 8804017
[No Abstract] [Full Text] [Related]
7. [Diagnosis and therapy for beta2-microglobulin amyloidosis in the K/DOQI guideline].
Higuchi N; Maruyama H
Clin Calcium; 2004 May; 14(5):744-9. PubMed ID: 15577036
[TBL] [Abstract][Full Text] [Related]
8. [Pathogenesis of dialysis amyloidosis].
Gejyo F; Hasegawa S; Homma N; Maruyama H; Maruyama S; Arakawa M
Nihon Rinsho; 1992 Jan; 50 Suppl():796-800. PubMed ID: 1578769
[No Abstract] [Full Text] [Related]
9. Dialysis amyloidosis.
Lancet; 1991 Aug; 338(8763):349-50. PubMed ID: 1677703
[No Abstract] [Full Text] [Related]
10. Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin.
Gejyo F; Suzuki S; Arakawa M
Ther Apher; 1997 May; 1(2):126-8. PubMed ID: 10225756
[TBL] [Abstract][Full Text] [Related]
11. High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results.
David S; Cambi V
Contrib Nephrol; 1999; 125():96-110. PubMed ID: 9895434
[No Abstract] [Full Text] [Related]
12. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
13. Dialysis-associated amyloidosis.
Sethi D
Ren Fail; 1993; 15(3):349-51. PubMed ID: 8516489
[TBL] [Abstract][Full Text] [Related]
14. beta 2-microglobulin and amyloidosis: who is at risk?
Davison AM
Nephrol Dial Transplant; 1995; 10 Suppl 10():48-51. PubMed ID: 8825433
[No Abstract] [Full Text] [Related]
15. Dialysis amyloidosis: current disease concepts and new perspectives for its treatment.
Gejyo F; Arakawa M
Contrib Nephrol; 1990; 78():47-59; discussion 59-60. PubMed ID: 2225843
[No Abstract] [Full Text] [Related]
16. Clinical aspects of dialysis-related amyloidosis.
Schäffer J; Floege J; Koch KM
Contrib Nephrol; 1995; 112():90-6. PubMed ID: 7554997
[No Abstract] [Full Text] [Related]
17. [Diagnostic and therapeutic aspects of dialysis-related amyloidosis].
Kopeć J
Przegl Lek; 2006; 63(7):567-72. PubMed ID: 17203811
[TBL] [Abstract][Full Text] [Related]
18. [Amyloidosis in patients undergoing long-term hemodialysis: elucidation of etiological mechanism and therapeutic stratigy].
Shimojyo F
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():56-60. PubMed ID: 15796057
[No Abstract] [Full Text] [Related]
19. Beta-2 microglobulin in ESRD: an in-depth review.
Winchester JF; Salsberg JA; Levin NW
Adv Ren Replace Ther; 2003 Oct; 10(4):279-309. PubMed ID: 14681859
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and management of dialysis-related amyloid bone disease.
Nangaku M; Miyata T; Kurokawa K
Am J Med Sci; 1999 Jun; 317(6):410-5. PubMed ID: 10372842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
